Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

Researchers conducted the IMPROVE trial to evaluate whether a 3-week pause in BTK inhibitor use would improve immunity after COVID-19 booster vaccination without negatively affecting disease control ...

Researchers from MIT and Scripps have unveiled a promising new HIV vaccine approach that generates a powerful immune response ...

This paper reports on a correlation between diminished cardiolipin content and the severity of steatohepatitis in human subjects. This is supported further by experimental evidence from mice in which ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

Results show the regimen of epcoritamab plus R-ICE could serve most patients as a bridge to either autologous stem cell ...

ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.

For countries where reimbursement for CAR T or bispecific antibodies is more limited, polatuzumab-based treatment may be all the more attractive, and POLARGO has the potential to be a new standard of ...

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

Amid rising concerns over a possible fresh wave of COVID-19 cases across the country, the Tamil Nadu government has announced ...